论文部分内容阅读
目的观察清开灵软胶囊制剂前体体外抗H1N1、H5N1、H7N9流感病毒的作用。方法通过测定细胞培养液上清血凝滴度(HA)和半数组织培养感染剂量(TCID_(50)),评价清开灵软胶囊制剂前体和利巴韦林注射液不同给药方式(灭活、治疗、中和、预防)对H1N1、H5N1和H7N9流感病毒的抑制作用,并且通过MTT法测定清开灵软胶囊制剂前体和利巴韦林注射液不同给药方式体外抗H1N1流感病毒作用。结果清开灵软胶囊制剂前体的最大无毒浓度为0.391 mg/ml,利巴韦林注射液的最大无毒浓度为3.907μg/ml。清开灵软胶囊制剂前体以预防方式给药可以明显抑制流感病毒增殖,能显著降低H1N1、H5N1和H7N9流感病毒的HA和TCID_(50),以治疗方式给药能明显降低H1N1流感病毒的HA和TCID_(50)(P<0.05或P<0.01)。清开灵软胶囊制剂前体和利巴韦林注射液抗H1N1流感病毒的半数有效浓度分别为0.25 mg/ml、2.19μg/ml,治疗指数分别为5.32、95.89。结论清开灵软胶囊制剂前体对H1N1、H5N1、H7N9流感病毒具有明显的预防作用,且对H1N1流感病毒具有良好的治疗作用。
Objective To observe the anti-H1N1, H5N1 and H7N9 influenza virus activity of Qingkailing soft capsule preparation in vitro. Methods Different doses of Qingkailing soft capsule preparation and ribavirin injection were evaluated by measuring the HA titer and TCID_ (50) of the cell culture supernatant. H1N1, H5N1 and H7N9 influenza viruses by MTT assay, different anti-H1N1 influenza viruses in vitro by different administration methods of Qingkailing soft capsule preparation precursor and ribavirin injection effect. Results The maximum non-toxic concentration of Qingkailing soft capsule preparation precursor was 0.391 mg / ml, and the maximum non-toxic concentration of ribavirin injection was 3.907 μg / ml. Qing Kai Ling soft capsule preparations of precursors in a preventive manner can significantly inhibit the proliferation of influenza virus, can significantly reduce the H1N1, H5N1 and H7N9 influenza virus HA and TCID_ (50), the treatment can be administered can significantly reduce the H1N1 influenza virus HA and TCID 50 (P <0.05 or P <0.01). The median effective concentrations of Qingkailing soft capsule preparation precursor and ribavirin injection anti-H1N1 influenza virus were 0.25 mg / ml and 2.19 μg / ml respectively, and the therapeutic indexes were 5.32 and 95.89 respectively. Conclusion Qingkailing Soft Capsule preparation has obvious preventive effect on H1N1, H5N1 and H7N9 influenza viruses and has a good therapeutic effect on H1N1 influenza virus.